Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

121. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. (PubMed)

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Direct-acting antiviral agents (DAAs) are used increasingly to treat hepatitis C virus (HCV) infection. Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients with HBV-HCV co-infection. Hepatitis B virus reactivation, defined as an abrupt increase (...) in HBV replication in patients with inactive or resolved HBV infection, may result in clinically significant hepatitis.To assess whether HBV-R is a safety concern in patients receiving HCV DAAs.Descriptive case series.U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).29 patients with HBV-R receiving HCV DAAs.Clinical and laboratory data.The FDA identified 29 unique reports of HBV-R in patients receiving DAAs from 22 November 2013 to 15 October 2016. Two cases resulted

2017 Annals of Internal Medicine

122. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation: A pre-specified analysis from the randomized minimizing adverse haemorrhagic events by transradial access site and systemic implementation of angi

Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation: A pre-specified analysis from the randomized minimizing adverse haemorrhagic events by transradial access site and systemic implementation of angi To assess whether radial compared with femoral access is associated with consistent outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS).In the Minimizing (...) Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) programme patients were randomized to radial or femoral access, stratified by STEMI (2001 radial, 2009 femoral) and NSTE-ACS (2196 radial, 2198 femoral). The 30-day co-primary outcomes were major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding In the overall study population, radial

Full Text available with Trip Pro

2017 EvidenceUpdates

123. Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study

Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Mayor S, Baines E, Vincent C, Lankshear A, Edwards A, Aylward M, Hogan H, Harper P, Davies J, Mamtora A, Brockbank E & Gray J Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mayor S, Baines E, Vincent C, Lankshear A, Edwards A, Aylward M, Hogan H, Harper P, Davies J, Mamtora A, Brockbank E & Gray J. Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study. Health Services and Delivery Research 2017; 5(9) Authors' objectives Despite

2017 Health Technology Assessment (HTA) Database.

124. Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs. (PubMed)

Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs. Unlike pharmacological randomized controlled trials (RCTs), manual-therapy RCTs do not always report adverse events (AEs). The few manual-therapy RCTs that provide information on AEs are frequently without details, such as the type and-, severity of the AE and reason for withdrawal.To prospectively report all AEs in a chiropractic spinal manipulative therapy (CSMT

Full Text available with Trip Pro

2017 Musculoskeletal science & practice

125. Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study

Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverse events study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

2017 NIHR HTA programme

126. Preventing drug-related adverse events following hospital discharge: the role of the pharmacist (PubMed)

Preventing drug-related adverse events following hospital discharge: the role of the pharmacist Transition of care (ToC) points, and in particular hospital admission and discharge, can be associated with an increased risk of adverse drug events (ADEs) and other drug-related problems (DRPs). The growing recognition of the pharmacist as an expert in medication management, patient education and communication makes them well placed to intervene. There is evidence to indicate that the inclusion

Full Text available with Trip Pro

2017 Integrated pharmacy research & practice

127. Adverse events associated with the use of cervical spine manipulation or mobilization and patient characteristics: A systematic review. (PubMed)

Adverse events associated with the use of cervical spine manipulation or mobilization and patient characteristics: A systematic review. Cervical spinal manipulation (CSM) and cervical mobilization are frequently used in patients with neck pain and headache. Pre-manipulative cervical instability and arterial integrity tests appear to be unreliable in identifying patients at risk for adverse events. It would be valuable if patients at risk could be identified by specific characteristics during (...) the preliminary screening. Objective was to identify characteristics of 1) patients, 2) practitioners, 3) treatment process and 4) adverse events (AE) occurring after CSM or cervical mobilization. A systematic search was performed in PubMed, Embase, CINAHL, Web-of-science, AMED, and ICL (Index Chiropractic Literature) up to December 2014. Of the initial 1043 studies, 144 studies were included, containing 227 cases. 117 cases described male patients with a mean age of 45 (SD 12) and a mean age of 39 (SD 11

2017 Musculoskeletal science & practice

128. Trends in Perioperative Major Adverse Cardiovascular and Cerebrovascular Events associated with Non-Cardiac Surgery (PubMed)

Trends in Perioperative Major Adverse Cardiovascular and Cerebrovascular Events associated with Non-Cardiac Surgery Major adverse cardiovascular and cerebrovascular events (MACCE) are a significant source of perioperative morbidity and mortality following noncardiac surgery.To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncardiac surgery and to identify surgical subtypes associated with cardiovascular events using a large administrative database (...) occurred in 317 479 hospitalizations (3.0%), corresponding to an annual incidence of approximately 150 000 events after applying sample weights. Major adverse cardiovascular and cerebrovascular events occurred most frequently in patients undergoing vascular (7.7%), thoracic (6.5%), and transplant surgery (6.3%). Between 2004 and 2013, the frequency of MACCE declined from 3.1% to 2.6% (P for trend <.001; adjusted odds ratio [aOR], 0.95; 95% CI, 0.94-0.97) driven by a decline in frequency

Full Text available with Trip Pro

2017 JAMA cardiology

129. The effect of endotracheal tubes versus laryngeal mask airways on perioperative respiratory adverse events in infants: a randomised controlled trial. (PubMed)

The effect of endotracheal tubes versus laryngeal mask airways on perioperative respiratory adverse events in infants: a randomised controlled trial. Perioperative respiratory adverse events (PRAE) are the most common critical incidents in paediatric anaesthesia and occur more often in infants. Use of laryngeal mask airways (LMAs) is associated with reduced PRAE compared with endotracheal tubes in older children (>1 year). We aimed to evaluate the effect of these devices on the incidence

Full Text available with Trip Pro

2017 Lancet

130. Randomised controlled trial: Intensive blood pressure lowering provides no additional benefits and results in more adverse events

Randomised controlled trial: Intensive blood pressure lowering provides no additional benefits and results in more adverse events Intensive blood pressure lowering provides no additional benefits and results in more adverse events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Intensive blood pressure lowering provides no additional benefits and results in more adverse events Article Text Therapeutics/Prevention Randomised controlled trial

2017 Evidence-Based Medicine (Requires free registration)

131. Cohort Study: Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder

Cohort Study: Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adverse events associated with mood stabiliser treatment should be continuously monitored

2017 Evidence-Based Medicine (Requires free registration)

132. In adults with ankle osteoarthritis (OA), is total ankle replacement/fusion/debridement better than no treatment for pain and function, risks and harms and adverse events?

In adults with ankle osteoarthritis (OA), is total ankle replacement/fusion/debridement better than no treatment for pain and function, risks and harms and adverse events? Getting Evidence into Clinical Practice: Musculoskeletal Research Facilitation Group (CAT Group) Date: February 2018 CAT Lead: Jo Pike Date CAT completed: February 2018 joannapike@nhs.net Date CAT to be reviewed: February 2021 Specific Question: In adults with ankle Osteoarthritis (OA) A is total ankle replacement/fusion (...) /debridement better than no treatment for pain and function, risks and harms and adverse events? Clinical bottom line At present, there are no studies that compare surgical intervention with no treatment for the management of patients with ankle OA. Due to the lack of evidence of comparing no treatment with surgical intervention for pain and function, risks and harms and adverse events, then clinical practice should remain unchanged. Within the available evidence, it is apparent that surgical intervention

2017 Public Health England

133. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. (PubMed)

Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Concerns have been raised about the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh. We assessed adverse outcomes after first, single mesh procedures and comparable non-mesh procedures.We did a cohort study of women in Scotland aged 20 years or older

Full Text available with Trip Pro

2016 Lancet

134. Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event (PubMed)

Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event 30241172 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event. 1-4 10.1200/JGO.2016.007765 Adhikari Narayan N All authors: All India Institute of Medical Sciences, New Delhi, Delhi, India. Kumar Pavnesh P All authors: All India Institute of Medical Sciences, New Delhi, Delhi, India. Venkatesulu Bhanu P BP All authors: All India Institute

Full Text available with Trip Pro

2016 Journal of global oncology

135. Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events (PubMed)

Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events Anthrax postexposure prophylaxis (PEP) was recommended to 42 people after a laboratory incident that involved potential aerosolization of Bacillus anthracis spores in 2 laboratories at the Centers for Disease Control and Prevention in 2014. At least 31 (74%) individuals who initiated PEP did not complete either the recommended 60 days of antimicrobial therapy or the 3-dose vaccine regimen. Among the 29 (...) that discontinued the antimicrobial component of PEP, most (38%) individuals discontinued PEP because of their low perceived risk of infection; 9 (31%) individuals discontinued prophylaxis due to PEP-related minor adverse events, and 10% cited both low risk and adverse events as their reason for discontinuation. Most minor adverse events reported were gastrointestinal complaints, and none required medical attention. Individuals taking ciprofloxacin were twice as likely (RR = 2.02, 95% CI = 1.1-3.6

Full Text available with Trip Pro

2016 Health security

136. Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing (PubMed)

Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing 27893112 2016 12 13 2018 12 02 1538-3598 316 20 2016 Nov 22 JAMA JAMA Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing. 2092-2093 10.1001/jama.2016.16392 Kessler Chad C Durham VA Medical Center, Durham, North Carolina. Ward Michael J MJ Vanderbilt University Medical Center, Nashville, Tennessee. McNaughton Candace D CD Vanderbilt University Medical Center, Nashville, Tennessee. eng K23 HL125670 HL (...) NHLBI NIH HHS United States K23 HL127130 HL NHLBI NIH HHS United States Editorial Comment United States JAMA 7501160 0098-7484 AIM IM JAMA. 2016 Nov 22;316(20):2115-2125 27893129 Drug-Related Side Effects and Adverse Reactions Humans Medication Errors Outpatients 2016 11 29 6 0 2016 11 29 6 0 2016 12 15 6 0 ppublish 27893112 2585959 10.1001/jama.2016.16392 PMC5779096 NIHMS934127 Can J Hosp Pharm. 2015 May-Jun;68(3):202-9 26157181 JAMA. 2016 Nov 22;316(20):2115-2125 27893129 J Med Ethics. 2015 Nov;41

Full Text available with Trip Pro

2016 JAMA

137. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. (PubMed)

US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. The Patient Protection and Affordable Care Act of 2010 brought attention to adverse drug events in national patient safety efforts. Updated, detailed, nationally representative data describing adverse drug events can help focus these efforts.To describe the characteristics of emergency department (ED) visits for adverse drug events in the United States in 2013-2014 and describe changes in ED visits for adverse drug (...) events since 2005-2006.Active, nationally representative, public health surveillance in 58 EDs located in the United States and participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.Drugs implicated in ED visits.National weighted estimates of ED visits and subsequent hospitalizations for adverse drug events.Based on data from 42 585 cases, an estimated 4.0 (95% CI, 3.1-5.0) ED visits for adverse drug events occurred per 1000

Full Text available with Trip Pro

2016 JAMA

138. CJEM Infographic: Adverse Events Following Pediatric Catheterization

CJEM Infographic: Adverse Events Following Pediatric Catheterization CJEM Infographic: Adverse Events Following Pediatric Catheterization - CanadiEM CJEM Infographic: Adverse Events Following Pediatric Catheterization In , by Simon Huang November 18, 2016 This month CanadiEM is featuring an article from the Canadian Journal of Emergency Medicine (CJEM) that focuses on the use of pediatric catheterization in the emergency department (ED). Currently, catheterization is used in the pediatric ED (...) for diagnosing young children with a suspected urinary tract infection (UTI). However, there have been few studies that have looked at short-term adverse events in this population. As shown in this CanadiEM infographic, this study by Ouellet-Pelletier et al . 1 set out to assess adverse events in the week following diagnostic urinary catheterization in children in the pediatric ED. Specifically, a prospective observational study was performed in a single ED at Sainte-Justine University Hospital. Parents

2016 CandiEM

139. Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews. (PubMed)

Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews. The prevalence of knee osteoarthritis (OA)/degenerative joint disease (DJD) is increasing in the USA. Systematic reviews of treatment efficacy and adverse events (AEs) of hyaluronic acid (HA) injections report conflicting evidence about the balance of benefits and harms. We review evidence on efficacy and AEs of intraarticular (...) : pooled analysis of ten placebo-controlled, blinded trials showed a standardized mean difference of -0.23 (95 % confidence interval (CI) -0.45 to -0.01) favoring HA at 6 months. Studies reported few serious adverse events (SAEs) and no significant differences in non-serious adverse events (NSAEs) (relative risk (RR) [95 % CI] 1.03 [0.93-1.15] or SAEs (RR [95 % CI] 1.39 [0.78-2.47]). A recent prior systematic review reported similar functional outcomes, but significant SAE risk. Differences in SAE

Full Text available with Trip Pro

2016 Systematic Reviews

140. Risk of Serious Adverse Events and Fatal Adverse Events with Sorafenib in Patients with Solid Cancer: A meta-analysis of phase 3 Randomized Controlled Trials. (PubMed)

Risk of Serious Adverse Events and Fatal Adverse Events with Sorafenib in Patients with Solid Cancer: A meta-analysis of phase 3 Randomized Controlled Trials. Sorafenib is a multikinase-tyrosine kinase inhibitor commonly used in a variety of cancers. There are concerns about the increased risk of serious adverse events (SAEs) and fatal adverse events (FAEs) with sorafenib. We performed an up-to-date meta-analysis of all phase 3 randomized controlled trials (RCTs) of sorafenib to quantify

Full Text available with Trip Pro

2016 Annals of oncology : official journal of the European Society for Medical Oncology